NCT03908307已完成4 期
A 12-month, Open-label, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® Implant 700 µg (Dexamethasone) on Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (YANGTZE Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 150
- 试验地点
- 9
- 主要终点
- Mean change in visual acuity from Baseline
研究概览
简要总结
This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •Patient diagnosed with macular edema due to RVO (either BRVO or CRVO, non-ischemic)
- •Retinal thickness ≥ 300 μm by SD-OCT in the central 1 mm macular subfield of the study eye at the Screening visit
- •BCVA score of 19 to 73 letters (approximately 20/400 to 20/40 Snellen equivalent) in the study eye measured by ETDRS method at Screening
- •< 3 months of macular edema duration
- •Treatment-naive patients (ie, have not previously received any treatment for macular edema secondary to RVO)
排除标准
- •Uncontrolled systemic disease
- •Presence of/history of any ocular condition other than macular edema that affects visual acuity (eg, cataract, severe macular ischemia, foveal atrophy, age-related macular degeneration, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, prior macular detachment)
- •Any of the following ≤ 3 months before study entry or anticipated need within the coming 3 months:
- •Intraocular surgery
- •Laser photocoagulation
- •Intraocular injection
- •Periocular steroid injection
- •Vitrectomized eye
- •Aphakic eyes with ruptured posterior lens capsule or presence of an ACIOL, iris or transscleral fixated intraocular lens
- •History of marked IOP elevation in response to steroid treatment that (a) required IOP-lowering treatment, (b) resulted in a >10 mm Hg increase in IOP from predose, or (c) resulted in IOP >25 mm Hg
- •History of glaucoma or ocular hypertension (IOP > 21 mm Hg), or optic nerve head change consistent with glaucoma damage, and/or glaucomatous visual field loss in the study eye (patients with a history of previous angle closure that has been successfully treated with either a laser or surgical peripheral iridotomy [PI] are allowed as long as the visual fields have been stable for > 1 year prior to study entry and the patient has been and can be safely dilated).
- •Any active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at the Screening visit
- •Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception
- •Any condition that may interfere or preclude participation in the study
- •Use of systemic steroids (e.g., oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to Baseline or anticipated use at any time during the study (inhaled, intranasal, and intra-articular/intrabursal corticosteroids are allowed)
- •Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating agents within 3 months prior to Baseline or anticipated use at any time during the study
- •Use of warfarin or heparin within 2 weeks prior to Baseline or anticipated use within the study period
- •Known allergy, hypersensitivity or contraindication to the study medication, its components, fluorescein or povidone iodine
- •Current enrollment in another drug or device study within 30 days prior to Baseline
研究组 & 干预措施
Study Eye
Experimental
OZURDEX implant 700 μg
干预措施: OZURDEX (Drug)
结局指标
主要结局
Mean change in visual acuity from Baseline
时间窗: At Month 6
Determined by best corrected visual acuity (BCVA)
Proportion of patients with a BCVA improvement of 15 letters or more compared to Baseline
时间窗: At Month 6
Measured using the ETDRS visual acuity protocol
BCVA average change from Baseline in area under the curve (AUC) analysis
时间窗: At Month 6
次要结局
- Mean change from Baseline in Central Retinal Thickness (CRT)(At Months 6 and 12)
- Mean change from Baseline in BCVA(After first follow-up visit, at each injection, and at Month 12)
- Mean change from Baseline in the National Eye Institute (NEI) Visual Function Questionnaire (VFQ)-25(At Months 6 and 12)
- Mean number of OZURDEX injections(During the 12-month study)
- Mean retreatment interval in months(During the 12-month study)
- Proportion of patients with 2nd injection(During the 12-month study)
- Proportion of patients with 3rd injection(During the 12-month study)
- Time to 2nd injection(During the 12-month study)
- Time to 3rd injection(During the 12-month study)
- Correlation between the change of BCVA and extent of leak by fluorescein angiography (FA)(At Month 6)
研究者
研究点 (9)
Loading locations...
相似试验
进行中（未招募）
4 期
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisNCT06396039Bristol-Myers Squibb84
已完成
不适用
A Long-Term Safety Study of OZURDEX® in Clinical PracticeMacular EdemaUveitis, PosteriorRetinal Vein OcclusionNCT01539577Allergan875
已完成
不适用
Study on OsseoSpeed™ TX Implants in a Chinese PopulationPartially Edentulous JawNCT01346683Dentsply Sirona Implants and Consumables45
已完成
4 期
A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never TreatedDiabetic Macular EdemaNCT03953807Allergan82
已完成
4 期
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein OcclusionMacular EdemaRetinal Vein OcclusionNCT01903720Allergan71